Retatrutid 10mg we yu de yuz

▎ Ritatrutid Strukchɔ

▎ Risach we dɛn kɔl Retatrutid

Wetin na di risach bakgrɔn fɔ Retatrutid?

Fɔ fat na wan pan di big prɔblɛm dɛn we de mek pipul dɛn gɛt wɛlbɔdi tide. If pɔsin fat, i kin mek i gɛt difrɛn wɛlbɔdi prɔblɛm dɛn, lɛk tayp 2 dayabitis, sik dɛn we de mek pɔsin in at ɛn blɔd, ay blɔd prɛshɔn, dislipidemia, ɛn fat liva sik we nɔ de drink rɔm. Wit di kɔntinyu we di pipul dɛn we fat de bɔku, pipul dɛn de aks fɔ nyu tritmɛnt dɛn we go ebul fɔ manej di bɔdi wet fayn fayn wan ɛn mek di wɛlbɔdi biznɛs bɛtɛ ^[1] . Pan ɔl we fɔ chenj di we aw pɔsin de liv in layf, lɛk fɔ du mɔ bɔdi wok ɛn fɔ ridyus di it we dɛn de it, na di men we fɔ mek dɛn nɔ gɛt bɔku bɔku bɔdi, fɔ mek dɛn nɔ gɛt bɔku bɔku bɔdi fɔ lɔng tɛm stil na prɔblɛm fɔ bɔku big pipul dɛn we di sik dɔn afɛkt. rεtatrutid na nכvel tripl rεsεpכta agonist we de akt pan di glukכn lεk pεptida-1 rεsεpכta (GLP-1R), glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta (GIPR), εn glukagכn rεsεpכta (GCGR). dis mכlti-rεsεptor mεkanism fכ akshכn de gi am yכnik advantej dεm fכ lכs weit. we yu kכmpεr wit di weit lכs dכg dεm we de akt pan wan rεsεpכta, Retatrutid kin mכr kכmprεhεnsiv rεgεl di bכdi in mεtabolik prכsεs dεm ^[1] . rεtatrutid de ajɔst di wet lכs bay we i de rεgεl mכltipכl כmon rεsεpכta dεm. I nɔ jɔs gɛt siriɔs wet lɔs ifɛkt bɔt i gɛt rili smɔl gastrointestinal sayd ɛfɛkt dɛn bak. Apat frɔm dat, we yu kɔmpia am wit ɔda nyu weit lɔs drɔgs, Retatrutid, as triplɛ riseptɔ agonist, gɛt mɔ pawaful weit lɔs ifɛkt ɛn bɔku bɔku pipul dɛn we dɛn kin yuz.

Wetin na di mɛkanism fɔ akshɔn fɔ Retatrutid?

di mεkanism fכ akshכn fכ Retatrutid mεnli kכmכt frכm in agonistik ifekt dεm pan mכltipכl rεsεpכta dεm. fכs, in agonistik ifekt pan di glukagon-layk pεptida-1 rεsεpכta (GLP-1R) de inkrεs insulin sekreshכn, inhεbit glukagon sekreshכn, rεdכks di blכd glukכs lεvεl, εn di sem tεm de delay di gεstrik εmpti, inkrεs di satiety, εn i de ridyus di it we yu de it ^[2] . sεkכn, in agonistik ifekt pan di glukכs-dipεndεnt insulinotropik polipεptida rεsεptכr (GIPR) kin promuot insulin sekreshכn, εnhans glukכs yutilizeshכn, εn gεt impak pan fεt mεtabolism, inhεbit lipolysis εn protεkt fεt sεntesis ^[2] . pan tap dat, pan כl we di agonistik ifekt we Retatrutid gεt pan di glukagon rεsεpכta (GCGR) kin כlwayz fכ protεkt glycogenolysis εn gluconeogenesis insay di liva, we de inkrεs di blכd glukכs lεvεl, כnda di akshכn fכ Retatrutid, dis ifekt we de inkrεs di blכd glukכs de כfset bay di ifekt dεm we di כda tu rεsεptor dεm de gi. di sem tεm, i de mek di lipolysis kכmכt εn i de ridyus di fεt we de kכmכt ^[2] . dis mכlti-target mכd fכ akshכn kin bi mכr ifektiv fכ trit fכ fat pas singl rεsεptכr agonist dεm.

bay we i de aktibכt dεn tri rεsεpכta dεm ya wan tεm, Retatrutid kin εksyεrt difrεn mεtabolik rεgεdyushכn ifekt dεm εn prodyuz tεrapi ifekt pan fכ fat εn sik dεm we de kכmכt wit am. pan tεm fכ rεgεl di blכd glukכs lεvεl, biכs fכ di aktibכshכn fכ GLP-1R εn GIPR we de promuot insulin sekreshכn εn inhibit glukagon sekreshכn, εn di aktibכshכn fכ GCGR we de כfset bay di ifekt dεm we di כda tu rεsεpכta dεm de gi, Retatrutid kin rigul di blכd glukכs lεvεl fayn fayn wan, we na big minin fכ di tritmεnt fכ tayp 2 dayabεtis ^{[1, 2]} . pan tεm fכ ridyus fεt akyumyuleshכn, di aktibכshכn fכ GCGR de promuot lipolysis εn ridyus fεt akyumyuleshכn. di sem tεm, di aktibכshכn fכ GLP-1R de inkrεs di satεti εn ridyus di it we yu de it, we de ridyus di fεt sεntesis mכr ^{[1, 2]} . Apat frɔm dat, Retatrutid gɛt fayn fayn ɛfɛkt bak pan di sik we nɔ gɛt rɔm we gɛt fat liva. I kin mek di fat we de insay di liva nɔ bɔku ɛn i kin mek di liva wok fayn. Wan randomized, double-blind, placebo-controlled trial sho se di avrej rilitiv chenj na di liva fat na di Retatrutid tritmɛnt grup na 24 wiks bin rili smɔl pas di wan na di plasɛbo grup ^[3]..

HbA1c, bɔdi wet, blɔd prɛshɔn, ɛn lipid dɛn Data na lɛst-skwea min (wit mistek bar dɛn we de sho SE dɛn) frɔm di ɛfifikɛshɔn analisis sɛt, pas nɔmɔ dɛn no ɔda we.

Sos:PubMed ^{[4] we dɛn pul am.}

aw εksakכt wan Retatrutid de rεgεl di glukכs mεtabolism afta i aktibכt di tri rεsεpכta dεm?

rεtatrutid de rεgεl di bכdi glukכs tru mכltipכl mεkanism dεm, we inklud fכ aktibכt GLP-1 εn GIP rεsεpכta dεm, fכ mek insulin sekreshכn, inhεbit glukagon sekreshכn, delay gastric εmpti, rεgεl fεt mεtabolism, εn ridyus ANGPTL3/8 lεvεl. we i kam pan bכdi glukכs rεguleshכn, Retatrutid de akt pan GLP-1 εn GIP rεsεpכta dεm, i de protεkt di sεnsitiviti fכ di pankrεas β sεl dεm to glukכs, i de sεntez εn rilis insulin, εn afta dat i de protεkt di כptek εn yutilizeshכn fכ glukכs bay tisu dεm, achy di ifekt fכ ridyus di glukכs na di bכdi ^{[4, 5]} .In wan stכdi fכ tayp 2 dayabitis pasεnshכn dεm, Retatrutid sho wan siknifikant ifekt fכ ridyus glycated hemoglobin (HbA1c), we bכku bεnεfit frכm in rol fכ stimulat insulin sekreshכn (Rosenstock J, 2023). di sem tεm, we dεn aktibכt di GLP-1 rεsεpכta kin inhεbit di sekreshכn fכ glukagon bay pankrεas α sεl dεm, we de mek di bכdi glukכs nכ tu hכy. insay klinik stכdi dεm, dεn si se di glukכn lεvεl fכ di pasεn dεm we de yuz Retatrutid dכn dכn, we in tכn de εp fכ mεnten di stεbiliti fכ di blכd glukכs ^{[4, 5]} . fכ aktibכt GLP-1 εn GIP rεsεpכta dεm kin delay bak di rεt we di gεstrik εmpti, slo dכn di dijeshכn εn absכpshכn fכ it, εn rεdכks di shap rise in postprandial bכdi glukכs. stכdi dεn sho se di gastric εmpti tεm fכ di pasεn dεm we dεn trit wit Retatrutid kin sכmtεm lכng afta dεn it, we de rεdכks di pik valyu fכ di postprandial bכdi glukכs ^[4]..

di rεguleshכn fכ fεt mεtabolism bay Retatrutid de afekt glukכs mεtabolism bak indaykt wan. fכ egzampl, insay stכdi dεm pan pipul dεm we fat, dεn fכnshכn se Retatrutid kin ridyus di lεvεl dεm fכ triglisεrayd (TG), lכw dεnsiti lipoprotein (LDL), εn vεri lכw dεnsiti lipoprotein (VLDL) kכlestכl ^{[2, 6]} . dis impruvmεnt na di lipid mεtabolism kin riliyt to di impruvmεnt fכ insulin sεnsitiviti, we de kכntribyut fכ kכntrכl glukכs na di bכdi. sכm spεshal, afta Retatrutid tritmεnt, di plasma 3-haydroksibutyrik asid (3-HB) de inkrεs, we de kכmpan wit inkrεs pan 3-haydroksibutyrilkarnitin (C ₄OH), di rεshכn fכ asetilkarnitin to fri kכnitin (C ₂/C ₀), εn mεdiכm-chεn asilkarnitin, we de sho se lipolysis de εnhans insay adipos tisu εn inkrεs dipεndεns pan fεt ɔksidɛshɔn.

Retatrutid kin ridyus di totכl dihaydroseramid dεm (DhCers) bak, εn dis chenj de sho se di insulin sεnsitiviti de bכku, di hεpatik steatosis we de ridyus, εn di sεstεmik inflameshn ^[6] .At di sem tεm, Retatrutid kin ridyus di kכnsantreshכn fכ di ANGPTL3/8 kכmpleks bak na di sεrum fכ di tayp 2 dayabεtis pasεnshכn dεm, we de rεgεl glukכs mεtabolism ^[7] . ANGPTL3/8 na di mכst ifektiv sirkulεt inhibito fכ lipoprotein lipase (LPL), εn in sεrum lεvεl de rilayt dairekt to TG εn lכw-dεnsiti lipoprotein kכlestכl (LDL-C). rεtatrutid de ridyus di lεvεl fכ ANGPTL3/8, we kin rεgεl di glukכs mεtabolism bay we i de ridyus di triglisεrayd-rich lipoprotein dεm ^[7]. .

Insay us aspek dɛn Retatrutid de sho in ifɛkt dɛn?

Impɔtant ifɛkt we pɔsin kin gɛt we i de lɔs yu wet: 

Retatrutid dɔn sho signifyant weit lɔs ifɛkt dɛn insay bɔku klinik trial dɛn. Fɔ ɛgzampul, insay wan klinik stɔdi we involv 338 big pipul dɛn ^[2] , di pasɛnt dɛn we dɛn trit wit difrɛn doz dɛn fɔ Retatrutid bin gɛt bɔku bɔku weit lɔs we dɛn ol 48 wik. Na dɛn wan ya, di pasɛnt dɛn we bin de na di 12mg doz grup bin gɛt wet lɔs we na 24.2%, ɛn wan ay prɔpɔshɔn pan di pasɛnt dɛn bin ajɔst di wet lɔs to difrɛn digri dɛn. Fɔ ɛgzampul, pan di pasɛnt dɛn we bin de tek 4mg, 8mg, ɛn 12mg dos, 92%, 100%, ɛn 100% pan di pasɛnt dɛn bin lɔs 5% ɔ mɔ pan dɛn bɔdi wet, rispɛktvɔli. Insay wan ɔda stɔdi ^[8] , tu randomized kɔntrol trayal we involv 353 tayp 2 dayabitis pasɛnt dɛn sho se we dɛn kɔmpia am wit di plasɛbo, Retatrutid kin ridyus di bɔdi wet fɔ di pasɛnt dɛn bad bad wan bay 11.89kg ɛn ridyus glycated hemoglobin (HbA1C). Apat frɔm dat, insay wan trayal pan big pipul dɛn we nɔ gɛt dayabitik we fat, Retatrutid bin mek di sik pipul dɛn wet lɔs 24.2%, ɛn 83% pan di pasɛnt dɛn lɔs 15% ɔ mɔ pan dɛn bɔdi wet we dɛn ol 48 wik. Dɛn rizɔlt ya sho se Retatrutid gɛt bɔku pawa fɔ lɔs yu wet.

Tritmɛnt fɔ tayp 2 dayabitis : . 

Retatrutid de sho bak sɔm pɔtnɛshɛl fɔ trit tayp 2 dayabitis. Insay sɔm klinik trayal dɛn, Retatrutid dɔn sho se di glycated hemoglobin (HbA1c) dɔn ridyus ɛn di wet we di pɔsin kin gɛt we i de du di doz. fכ egzampl, insay wan stכdi, pan tayp 2 dayabεtis pasεnshכn, Retatrutid sho wan siknifikant blכd glukכs kכntrכl ifekt, we ridyus glycated hεmoglobin bay 1.64% kכmpεr wit di plasεbo ^{[4, 8]} . Apat frɔm dat, insay wan randomized, double-blind, placebo, ɛn active-controlled parallel-group phase 2 trial, animal models wit tayp 2 dayabitis sho signifyant ridɔkshɔn pan glycated hemoglobin lɛvɛl ɛn wan doz-dipɛndent weit lɔs afta dɛn gɛt Retatrutid tritmɛnt ^[4] . dis kin bi fכ di kכmprεhεnsiv ifekt dεm we di dכg gεt pan GLP-1, GCGR, εn GIPR, we de impruv glukכs mεtabolism εn εnεji bεlε.

Impruvmɛnt fɔ di tin dɛn we kin mek pɔsin gɛt prɔblɛm wit di at ɛn di blɔd: 

rεtatrutid nכ kin כnli ridyus di bכdi wet bכt i kin impruv di kכdivaskyul risk fכktכ dεm, lεk di sεrum lipid prכfayl εn di glycated hemoglobin lεvεl. Dis de sho se wan klos pathophysiological kɔnekshɔn de bitwin fat ɛn di sik dɛm we de ambɔg di at, ɛn Retatrutid kin impruv di kadyovaskyuɛl wɛlbɔdi fɔ di wan dɛm we fat pasmak tru bɔku bɔku rod dɛm. fכ egzampl, fכ ridyus di nכn-HDL-C, apoB, εn LDLP lεvεl dεm kin ridyus di risk fכ atεrosklεrosis; fכ ridyus di glycated hεmoglobin lεvεl kin impruv di bכdi glukכs kכntrכl pan dayabεtis pasεnshכn, we de ridyus di risk fכ kכdivaskyul kכmplikεshכn dεm ^[8-10]. .

Tritmɛnt fɔ di sik we dɛn kɔl fat liva we nɔ gɛt rɔm (NAFLD): 

rεtatrutid na nכvel tripl rεsεptכr agonist pεptida we de tכk to di glukagכn rεsεptכr (GCGR), glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta (GIPR), εn glukagכn lεk pεptida-1 rεsεpכta (GLP-1R). Stɔdi dɔn sho se Retatrutid gɛt pɔtnɛshɛl fɔ trit di sik we nɔ gɛt rɔm we gɛt fat liva. Insay wan stכdi, dεn bin kכnεkt wan randomizεd, dכbl-blaynd, plasεbo-kכntrol trial we las 48 wiks pan patisipan dεm wit mεtabolik disfכnkshכn-asכsiet fεt liva sik εn wan liva fεt kכntεnt we ≥10%. di risal sho se na 24 wik, di avrej chenj dεm na di liva fεt rεlatεv to di beslayn in patisipan dεm we dεn trit wit difrεn dos dεm fכ Retatrutid (1mg, 4mg, 8mg, εn 12mg) na -42.9%, -57.0%, -81.4%, εn -82.4%, rispεktivli, we di wan na di plasεbo grup na bin +0.3% ^[3] . Dis sho se Retatrutid kin gɛt impɔtant tritmɛnt ifɛkt pan nɔ-alkohol fat liva sik.

Fכ kכnklud, as nכvel tripl rεsεptכr agonist, Retatrutid sho big pכtεnshal fכ trit fכ fat εn sik dεm we de kכmכt frכm am. i kin aktibכt di glukoz rεsεpכta, glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta, εn glukכn lεk pεptida-1 rεsεpכta, kכmprεhεnsivli rεgεl di bכdi in mεtabolism frכm mכltipכl dimεnshכn dεm, impruv bכdi glukכs kכntrכl, ridyus di bכdi wet, εn rεgεl di lipid mεtabolism. Di we aw Retatrutid dɔn kam, de briŋ nyu tritmɛnt opshɔn fɔ di wan dɛn we fat, tayp 2 dayabitis, ɛn ɔda sik dɛn. Dɛn de op se i go brok di limiteshɔn dɛm fɔ tradishɔnal singl riseptɔ agonist drɔgs, gi wan mɔ pawaful wɛpɔn fɔ sɔlv di siriɔs prɔblɛm dɛm we de bɔku mɔ ɛn mɔ fɔ fat ɛn mɛtabolik sik dɛm, fɔ mek dɛn divɛlɔp mɔ di rilayt mɛdikal fil dɛm, impruv di kwaliti fɔ layf fɔ di sik pipul dɛm, ɛn ridyus di soshal mɛdikal lod.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Rosenstock J na wan masta sabi bukman we gɛt bɔku pawa pan di mɛdikal fild, i de wok tranga wan wit institiushɔn dɛn lɛk di Yunivasiti ɔf Tɛksas Sawt Wɛstɛn Mɛdikal Sɛnta ɛn di Yunivasiti ɔf Tɛksas Dalas. I de du risach bak na sɛnta dɛn lɛk di Kanada VIGOR Senta ɛn Veloc Clin Res Ctr Med Siti. In risach de span ɛndokrinɔlɔji ɛn mɛtabolism, kadiɔvaskyuɛl sistɛm ɛn kadyolɔji, famakɔlɔji, ɛn ɛkspirimɛnt mɛrɛsin, wit di fɔs tin we i de tɔk bɔt dayabitis, fat, ɛn tritmɛnt dɛn we gɛt fɔ du wit am ɛn divɛlɔpmɛnt fɔ drɔgs. J Rosenstock dɔn gɛt bɔku sakrifays pan klinik mɛrɛsin, we dɛn kɔl am Highly Cited Researcher frɔm 2017 to 2024. Dis de sho di ay impak ɛn bɔku pipul dɛn we dɛn no bɔt in wok. Tru kolaboreshɔn wit bɔku risach institiushɔn dɛm, i dɔn saksesful fɔ translet di bɛsis risach fayndin dɛm to klinik aplikeshɔn, bɛnifit pasɛnt dɛm wit mɛtabolik ɛn kadivaskyul sik dɛm ɛn advans mɛdikal sayɛns. Rosenstock J de list in di rεfrεns fכ saytεshכn [4].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Kaur M, Misra S. Wan rivyu fɔ wan invɛstigeshɔn drɔg retatrutide, wan nyu tripl agonist ɛjɛn fɔ di tritmɛnt fɔ ɔbisiti[J]. Yuropian Jɔnal fɔ Klinik Famakɔlɔji, 2024,80(5):669-676.DOI:10.1007/s00228-024-03646-0.

[2] Jastreboff A. M., Kaplan L. M., Frias J. P., ɛn ɔda pipul dɛn. Tripul-Hכmon-Rεsεptor Agonist Rεtatrutid fכ Obesiti-A Faz 2 Trayal[J]. Nyu Ingland Jɔnal fɔ Mɛdisin, 2023,389(6):514-526.DOI:10.1056/NEJMoa2301972.

[3] Sanyal A. J., Kaplan L. M., Frias J. P., ɛn ɔda pipul dɛn. Tripul hכmon rεsεptכr agonist rεtatrutide fכ mεtabolik disfכnkshכn-asכsiet stεatotik liva sik: wan randomizεd fεz 2a trayal[J]. Nature Mεdisin, 2024,30 (7): 2037-2048.DOI: 10.1038/s41591-024-03018-2.

[4] Rosenstɔk J, Frias J, Jastrebɔf A. M., ɛn ɔda pipul dɛn. Retatrutid, na GIP, GLP-1 ɛn glukagon rεsεptכr agonist, fכ pipul dεm we gεt tayp 2 dayabεtis: wan randomizεd, dכbl-blaynd, plasεbo εn aktv-kכntrol, paralel-grup, fεz 2 trayal we dεn kכnεkt na di USA[J]. Lancet, 2023,402(10401):529-544.DOI:10.1016/S0140-6736(23)01053-X.

[5] Brzozowska P, Frańczuk A, Nowinska B, ɛn ɔda pipul dɛn. Retatrutid - rivכlyushכn rεsεntli divεlכp GLP agonist - litεrachכ rivyu[J]. Kwaliti in Spɔt, 2024.DOI: 10.12775/qs.2024.15.52125.

[6] Pirro V, Piɔsɔn M. J., Lin Y, ɛn ɔda pipul dɛn. Efεkt dεm we Tripl-Hכmon Risεptor Agonist Rεtatrutid gεt pan Lipid Prכfayl in Patisipεnt dεm wit Obesiti[J]. Dayabitis, 2024,73.DOI: 10.2337/db24-117-OR.

[7] Wen Y, Lemen D, Chen Y, ɛn ɔda pipul dɛn. rεdukshכn pan triglisεrayd-rich lipoprotein wit rεtatrutide in tayp 2 dayabεtis kin εksplen bay kכnkurεnt rεdukshכn pan ANGPTL3/8 lεvεl[J]. Yuropian At Jɔnal, 2024,45.DOI:10.1093/eurheartj/ehae666.2862.

[8] Lopez D. C., Pajimna J. T., Milan M. D., ɛn ɔda pipul dɛn. 7792 Efficacy of Retatrutid fכ Weight Ridukshכn εn In Cardiometabolic Efεkt dεm bitwin Adult dεm: A Sistεmatik Rivyu εn Mεta-Analysis[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(1):163-749.DOI:10.1210/jendso/bvae163.749.

[9] Nicholls S, Pirro V, Lin Y, ɛn ɔda pipul dɛn. tripl-hכmon rεsεptכr agonist rεtatrutide de impruv lipoprotein εn apolipoprotein profayl dεm sכmtεm insay patisipan dεm we fat כ ova wet[J]. Yuropian At Jɔnal, 2024,45.DOI:10.1093/eurheartj/ehae666.1501.

[10] Ray A. Retatrutid: na tripl inkrεtin rεsεptכr agonist fכ obesity mεnejmεnt[J]. Ekspɛkt Opinion Pan Investigeshɔn Drug, 2023,32(11):1003-1008.DOI:10.1080/13543784.2023.2276754.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.